Lilly's pediatric baricitinib trial closes enrollment after six delays
The Phase 3 sJIA study moved to Active, not recruiting with enrollment cut nearly in half from target, setting up a PediACR30 readout that will inform baricitinib's pediatric rheumatology footprint.
Executive Summary
- A Phase 3 pediatric trial of baricitinib in a rare, severe form of juvenile arthritis closed enrollment and shifted to Active, not recruiting, moving the program toward its primary readout.
- The trial's timeline has moved substantially since it started recruiting, with its enrollment target cut nearly in half and its completion date revised multiple times, though the sponsor's completion rate across its broader JAK franchise remains high.
- The primary endpoint measures a pediatric arthritis response rate at week 12, a test of whether an already-approved JAK inhibitor extends its effect into a narrower, systemic disease subtype rather than a new mechanism of action.
- The systemic JIA field carries few direct JAK-class competitors, with the closest being an upadacitinib trial in Phase 3, making this one of a small number of programs testing whether JAK inhibition holds in this specific pediatric population.
The status change
NCT04088396 is Eli Lilly's Phase 3 study of baricitinib, marketed as OLUMIANT, in participants from age 1 to under 18 with systemic juvenile idiopathic arthritis (sJIA), a rare and severe subtype of childhood arthritis marked by fever and systemic inflammation. The trial's status changed from Recruiting to Active, not recruiting on July 16, 2026, and its primary completion date moved from September 1 to October 1, 2026, the same day. The study randomizes participants across two cohorts: one comparing oral baricitinib against a subcutaneous tocilizumab reference arm in IL-6-inhibitor-naive patients, and a second providing open-label baricitinib to a broader age range. NCT04088396A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396
The endpoint bar
The primary endpoint measures the percentage of participants achieving an adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) response at week 12, a composite pediatric arthritis measure spanning joint counts, physician and parent global assessments, and functional ability. Secondary endpoints track disease activity score changes, pain severity, and pharmacokinetics through week 24. Because baricitinib is already approved in adult indications and has been tested in a separate broader juvenile idiopathic arthritis trial (NCT03773965), this readout tests replication of an established drug effect in a narrower systemic disease subtype rather than a first-in-class mechanistic question. NCT04088396A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396
The operational arc
The trial's primary completion date has been revised six times since 2020, moving from an original April 2023 target out to October 2026, a cumulative delay exceeding three years. Enrollment was cut from 103 to 58 participants in May 2024, alongside a narrowing of the completion window and updated eligibility language. Eli Lilly holds a 93% completion rate across 1,810 global trials and an 88% completion rate within its broader JAK inhibitor franchise, providing some context for the sponsor's execution record even as this individual study slipped repeatedly. NCT04088396A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396
Where it sits competitively
Only two other JAK1-directed industry trials are active in systemic JIA specifically, and the field's historical difficulty signal shows zero terminations recorded to date in this target-indication pairing. The closest direct comparator is AbbVie's upadacitinib, tested in a Phase 3 trial (NCT06454188) against a tocilizumab reference arm in the same disease, alongside filgotinib programs from Alfasigma extending JAK inhibition into juvenile arthritis more broadly. Given how few programs test JAK inhibition in this specific systemic subtype, a PediACR30 response that holds up against the tocilizumab-anchored comparator arm would be the result that meaningfully extends baricitinib's footprint in pediatric rheumatology beyond its existing juvenile idiopathic arthritis data.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.